Search research articles
Contact Us
Filters
Showing results (1-10 of 52) with videos related to
Page
of 6
Sort By:
Journal of Asthma and Allergy
|
March 26, 2011
Recommendation for optimal management of severe refractory asthma
Jaymin B Morjaria, Riccardo Polosa
Expert Review of Respiratory Medicine
|
May 19, 2010
Off-label use of omalizumab in non-asthma conditions: new opportunities
Jaymin B Morjaria, Riccardo Polosa
Drug Discovery Today
|
December 3, 2014
Emerging therapeutic strategies in COPD
Kesavan S Babu, Jaymin B Morjaria
Therapeutic Advances in Chronic Disease
|
December 20, 2012
Unusual asthma syndromes and their management
Jaymin B Morjaria, Jack A Kastelik
Therapeutic Advances in Respiratory Disease
|
March 11, 2015
Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
K Suresh Babu, Jaymin B Morjaria
Drug Discovery Today
|
March 13, 2010
Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD
Jaymin B Morjaria, Mario Malerba, Riccardo Polosa
Drug Discovery Today
|
November 29, 2011
Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects
Mario Malerba, Alessandro Radaeli, Jaymin B Morjaria
Current Opinion in Allergy and Clinical Immunology
|
December 15, 2010
Stratified medicine in selecting biologics for the treatment of severe asthma
Jaymin B Morjaria, Maria Proiti, Riccardo Polosa
Lung
|
March 4, 2017
Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
Jaymin B Morjaria, Alan Rigby, Alyn H Morice
Expert Opinion on Biological Therapy
|
March 23, 2013
Anti-IgE--emerging opportunities for Omalizumab
K Suresh Babu, Riccardo Polosa, Jaymin B Morjaria
Page
of 6
Search research articles
Search
Showing results (1-10 of 52) with videos related to
Sort By:
Page
of 6
Journal of Asthma and Allergy
|
March 26, 2011
Recommendation for optimal management of severe refractory asthma
Jaymin B Morjaria, Riccardo Polosa
Expert Review of Respiratory Medicine
|
May 19, 2010
Off-label use of omalizumab in non-asthma conditions: new opportunities
Jaymin B Morjaria, Riccardo Polosa
Drug Discovery Today
|
December 3, 2014
Emerging therapeutic strategies in COPD
Kesavan S Babu, Jaymin B Morjaria
Therapeutic Advances in Chronic Disease
|
December 20, 2012
Unusual asthma syndromes and their management
Jaymin B Morjaria, Jack A Kastelik
Therapeutic Advances in Respiratory Disease
|
March 11, 2015
Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
K Suresh Babu, Jaymin B Morjaria
Drug Discovery Today
|
March 13, 2010
Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD
Jaymin B Morjaria, Mario Malerba, Riccardo Polosa
Drug Discovery Today
|
November 29, 2011
Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects
Mario Malerba, Alessandro Radaeli, Jaymin B Morjaria
Current Opinion in Allergy and Clinical Immunology
|
December 15, 2010
Stratified medicine in selecting biologics for the treatment of severe asthma
Jaymin B Morjaria, Maria Proiti, Riccardo Polosa
Lung
|
March 4, 2017
Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
Jaymin B Morjaria, Alan Rigby, Alyn H Morice
Expert Opinion on Biological Therapy
|
March 23, 2013
Anti-IgE--emerging opportunities for Omalizumab
K Suresh Babu, Riccardo Polosa, Jaymin B Morjaria
Page
of 6